University of California, Los Angeles CARE Center CRS (Site # 601)
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Landovitz, Raphael J
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
HPTN 083, NCT02720094: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Active, not recruiting
2/3
4570
US, RoW
Cabotegravir Oral Tablet, Oral cabotegravir, TDF/FTC tablets, Truvada, Placebo for TDF/FTC tablets, Placebo for Truvada, Placebo for cabotegravir oral tablet, Placebo for oral cabotegravir, CAB LA, Long acting cabotegravir, Injectable cabotegravir, Placebo for CAB LA, Placebo for long acting cabotegravir
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Gilead Sciences
HIV Infections
05/20
04/25
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Not yet recruiting
2
200
US
CAB LA, New formulation of CAB LA
ViiV Healthcare
HIV Infections
08/26
12/28
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24

Download Options